Recommended Major Nitrosamine Impurities : N-Nitroso Finerenone

Pharmaceutical Companies Face "Bottleneck" Problems in R&D?

CATO Helps Break Through Nitrosamine Impurity Challenges for Major Drug Products

In recent years, drug safety issues have received significant attention. Among these, nitrosamine impurities have become a "Sword of Damocles" hanging over pharmaceutical companies.

On March 28, 2025, the FDA updated its "Nitrosamine Impurities Acceptable Intake Limits" database. This update primarily added and adjusted acceptable intake limits for multiple nitrosamine impurities and expanded the substance categories determined by the prediction-based carcinogenic potency classification approach (CPCA), further strengthening drug safety regulations.

Image source: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/cder-nitrosamine-impurity-acceptable-intake-limits

For the highly anticipated innovative drug — Finerenone — research on its nitrosamine impurities has also captured industry attention.

Finerenone: A "Star Drug" in the Treatment of Chronic Kidney Disease

Finerenone is a non-steroidal mineralocorticoid receptor antagonist primarily used to treat adult patients with type 2 diabetes accompanied by chronic kidney disease, aiming to reduce the risks of kidney disease progression, end-stage renal disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization due to heart failure. According to Bayer’s 2024 annual report, the global sales of Finerenone in 2024 were 463 million euros (approximately 525 million USD), representing a 71.5% increase compared to 270 million euros in 2023.

As a crucial innovative drug in this therapeutic area, Finerenone has garnered significant attention in the global market, facing intense competition. Currently, numerous pharmaceutical companies are actively advancing its research and development, as well as the process of marketing authorization, striving to seize market opportunities.

Nitrosamine Impurities: A Roadblock in Drug Marketing Authorization

However, in the process of Finerenone's research, development, and marketing applications, many companies face a common challenge — nitrosamine impurity research. According to the latest regulatory requirements, applicant companies need to conduct comprehensive research and evaluation of potential nitrosamine impurities in drugs to ensure patient medication safety.

This aspect has become a major obstacle in many companies' application processes due to its complexity and technical difficulty, seriously affecting drug development and market launch timelines.

Where Lies the Difficulty? Focusing on the Challenges of Nitrosamine Finerenone

Among many potential nitrosamine impurities, nitroso-finerenone presents particularly prominent research difficulties due to its unique structural characteristics, bringing huge challenges to the industry:

• The complex molecular structure of Finerenone with multiple potential nitrosation sites makes it difficult to achieve high selectivity and purity when synthesizing target impurities.
• Development of sensitive and specific analytical methods is greatly hindered due to the lack of reference standards and the complexity of drug formulation matrices.
• Almost no standard nitroso-finerenone reference materials are available in the market, making research difficult to initiate.
• Multiple possible isomers add another layer of complexity

These difficulties have caused many pharmaceutical companies to halt progress at the nitrosamine impurity research stage, directly affecting product review progress and market launch timing.

Time is money, time is opportunity — can you afford more delays?

CATO Breaks Through! Solving the Nitroso-Finerenone Challenge

Facing the industry-recognized challenge of developing Nitrosamine Finerenone impurities, CATO, leveraging its profound expertise and technological innovation in impurity research, has overcome numerous technical barriers and successfully developed samples of this specific nitrosamine impurity! This provides a practical and professional solution for pharmaceutical companies struggling with this issue.

Now, CATO can offer the following professional services to help you easily overcome the bottleneck in nitrosamine impurity research and accelerate your product application process!

1. Providing Nitrosamine Impurity Reference Standards

CATO can provide nitroso-finerenone impurity products as precise and reliable reference materials for drug research, enabling effective quality control and helping accelerate analytical method development and validation processes.

N-Nitroso Finerenone

 Purchase Order Number: C4X-28808  

*For product COA or more information, please contact WhatsApp+86 13533180352

In addition to nitroso-finerenone impurity, CATO also provides other related nitrosamine impurities to meet customers' broader needs and supports customer trials.

2. Providing Professional Technical Reports

After professional technical assessment, if a product is confirmed not to have the risk of forming nitrosamine impurities, CATO can assist customers in issuing professional evaluation reports for submission to regulatory authorities or for explaining situations to quality inspection departments, meeting regulatory requirements and providing strong support for market applications.

After professional technical assessment, if a product is confirmed not to have the risk of forming nitrosamine impurities, CATO can assist customers in issuing professional evaluation reports for submission to regulatory authorities or for explaining situations to quality inspection departments, meeting regulatory requirements and providing strong support for market applications.

⏰ Limited stock, first come, first served!

Important Reminder

Since this product was launched, CATO has received numerous inquiries and purchase requests from pharmaceutical companies! CATO has completed small-batch production of nitroso-finerenone, but due to the high difficulty in developing such impurities, stock is limited! We are currently expanding production of nitroso-finerenone, with restocking in progress. Stock is tight, inquire soon to secure yours

Facing continuously growing market demand, please act promptly! We recommend that customers with needs immediately contact CATO sales personnel for consultation.

Stock quantities are limited; customers with needs are advised to contact CATO sales quickly. Scan the code for quotes and trial solutions.

*please contact WhatsApp+86 13533180352

Seize the Opportunity: Now is the best time to break through the bottleneck of nitrosamine impurity research! Hesitation may lead to longer development cycles and greater market losses.

Contact CATO sales personnel immediately for consultation; the earlier you act, the better you can seize the opportunity and accelerate your product application process!

CATO will conduct professional assessments based on customers' specific needs and provide corresponding trial samples or technical support.

Whether you need nitrosamine impurity reference standards for method development or professional reports proving specific nitrosamine impurities do not exist, CATO can provide strong support to help your product quickly pass review!

Project acceleration, time is of the essence

Welcome all customers to contact the CATO team

Working together to advance product implementation and compliant application work!